Albireo: Ipsen to acquire rare disease specialist Albireo in deal worth over $950m
The deal will strengthen the French biopharma's liver disease pipeline with the addition of Bylvay
Read full article »
Albireo is a Massachusetts-based biopharmaceutical firm that researches and develops novel bile acid modulators for the treatment of liver diseases.
Read more